Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806292 | Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study(ABH-uHCC) | recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| 1 |
| Sep 8, 2026 |
| clinicaltrials |
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06526338 | Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone | recruiting | Phase 2 | 315 | Robert C. MartinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07062055 | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases | recruiting | Phase 2 | 54 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05304481 | Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | Lukas Biomedical Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06187961 | HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma(CCGLC-011) | recruiting | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation(EMPIRE) | recruiting | Phase 2 | 20 | Benjamin SpielerOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06166576 | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis(RESOLVE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06178198 | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma(RESCUE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06773845 | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria(BEAT-UT7) | recruiting | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07222657 | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma | recruiting | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT07157033 | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001) | recruiting | Phase 1 / Phase 2 | 36 | Xerient PharmaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07209813 | GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 48 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT04965454 | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma(ExTRACT-HCC) | recruiting | Phase 2 | 80 | Queen's Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04939051 | Obeticholic Acid for Prevention in Barrett's Esophagus | recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma(SLIDE-HCC) | recruiting | Phase 2 | 140 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06904183 | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | recruiting | Phase 2 | 320 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05518903 | Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma | recruiting | Phase 2 | 130 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06576115 | Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer | recruiting | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07043270 | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC | recruiting | Phase 2 | 35 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT05132504 | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Baylor College of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | recruiting | Phase 2 | 122 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07381634 | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities | recruiting | Phase 2 | 134 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials